Study, year [Reference] | Participants | Number of patients | Interventions | Median Survival (Months) | Survival Rate (%) | Adverse Effects (Number of Patients) | ||||
---|---|---|---|---|---|---|---|---|---|---|
 |  |  |  |  | 1 yr | 2 yr | 3 yr | 4 yr | 5 yr |  |
Nygaard* et al. 1992 [24] | 106 patients Jan 1983–Jan 1988 Scandinavia, multi centre squamous cell < 75 years of age Karnofsky score > 50 T1, T2, Nx, M0 > 21 cm from incisors | 56 | cisplatin 20 mg/m2 × 5 days × 2 cycles bleomycin 10 mg/m2 × 5 days × 2 cycles + esophagectomy | 7 | 31 | 6 | 3 | - | - | respiratory, 3; leaks, 3; postoperative deaths, 6; hematologic, 1; alopecia, 1 |
 |  | versus | versus | versus | versus | versus | ||||
 |  | 50 | esophagectomy (laparotomy and right thoracotomy) | 7 | 34 | 13 | 9 | - | - | respiratory, 5; leaks, 2; postoperative deaths, 5 |
 |  |  |  |  | No difference in survival (p-value not reported). |  | ||||
Schlag 1992 [32] | 46 patients dates not reported Germany, single centre squamous cell < 68 years of age Karnofsky > 70 Stage I, II, III | 22 | cisplatin 20 mg/m2 × 5 days × 3 cycles 5-fluorouracil 1 g/m2 × 5 days × 3 cycles + esophagectomy | 7.5 | 20 | - | - | - | - | vomiting, 11; alopecia, 10; fever, 2; bone marrow suppression, 5; renal, 2; |
 |  | versus | versus | versus | versus | versus | ||||
 |  | 24 | esophagectomy (abdominothoracic or thoracoabdominocervical with gastric or colon interposition) | 5 | 32 | - | - | - | - | not reported |
 |  |  |  |  | No difference in survival (p = 0.91). |  | ||||
Maipang et al. 1994 [33] | 46 patients Aug 1988–Dec 1990 Thailand, single centre squamous cell < 75 years of age ECOG 1, 2. Stage I, II, III distal 2/3 esophagus | 24 | cisplatin 100 mg/m2 × 1 day × 2 cycles vinblastine 3 mg/m2 × 4 days × 2 cycles bleomycin 10 mg/m2 × 5 days × 2 cycles + esophagectomy | 17 | 58 | 31 | 31 | - | - | hematologic, 15; vomiting, 15; alopecia, 14; hepatic, 3; lung, 1; urologic, 8; perioperative deaths, 4 |
 |  | versus | versus | versus | versus | versus | ||||
 |  | 22 | esophagectomy (laparotomy, right thoracotomy with gastric or colon interposition) | 17 | 85 | 40 | 36 | - | - | none reported |
 |  |  |  |  | p = 0.186 Early survival better in surgery alone group. |  | ||||
Law et al. 1997 [34] | 147 patients Dec 1989–Jan 1995 Hong Kong, single centre squamous cell exclude non regional nodes, tracheal involvement, metastases | 74 | cisplatin 100 mg/m2 × 1 day × 2 cycles 5-fluorouracil 500 mg/m2 × 5 days × 2 cycles + esophagectomy | 16.8 | 60 | 44 | 38 | 28 | 28 | Anemia, 47; neutropenia, 43; thrombocytopenia, 12; renal, 24; vomiting, 34; electrolytes, 21; leaks, 3; pulmonary, 10; respiratory failure, 14; perioperative deaths, 5 |
 |  | versus | versus | versus | versus | versus | ||||
 |  | 73 | esophagectomy (transhiatal or Lewis-Tanner) | 13 | 50 | 31 | 14 | 14 | - | pulmonary, 11; respiratory failure, 22; perioperative deaths, 6 |
 |  |  |  |  | p = 0.17 Responders to CT lived longer but non-responders had lower median survival than controls (p = 0.03). Lower local recurrence with CT. |  | ||||
Kok et al. 1997 [35] [abstract] | 160 patients 1990–1996 Netherlands, multi-centered Squamous cell | 74 | cisplatin 80 mg/m2 × 1 day × 2 cycles, etoposide 100 mg IV × 2 days + 200 mg/m2 PO × 2 days × 2 cycles + esophagectomy Note: CT responders received an additional 2 cycles of CT prior to surgery while non-responders received only 2 cycles | 18.5 |  |  |  |  |  | toxic deaths, 1; alopecia, 67; renal, 10 |
 |  | versus | versus | versus |  |  |  |  |  | versus |
 |  | 74 | esophagectomy (transhiatal). | 11 |  |  |  |  |  | none reported |
 |  |  |  |  | Not reported but median survival favoured CT (p = 0.002). |  | ||||
MRC OE02 2002 [37] | 802 patients Mar 1992 to June 1998 United Kingdom, multi-centered Resectable esophageal cancer 67% adenocarcinoma, 33% squamous or undifferentiated. | 400 | cisplatin 80 mg/m2 × 1 day × 2 cycles 5-fluorouracil 1 g/m2 × 4 days × 2 cycles + esophagectomy | 16.8 | 59 | 43 | 35 | 28 | 26 | postoperative complications, 41%; postoperative deaths, 10% |
 |  | versus | versus | versus | versus | versus | ||||
 |  | 402 | esophagectomy | 13.3 | 54 | 34 | 27 | 20 | 15 | postoperative complications, 42%; postoperative deaths, 10% |
 |  |  |  |  | Significant improvement in survival with chemotherapy HR = 0.79 (95% CI 0.67 to 0.93; p = 0.004) |  | ||||
Ancona et al. 2001 [48] | 94 | 47 | 5-FU 1000 mg/m2 CI d1-5 + Cisplatin 100 mg/m2 d1 | 25 | 75 | 55 | 44 | 42 | 34 | Gr. 3–4 neutropenia; 10 pts. |
 |  | versus | versus | versus | versus | versus | ||||
 |  | 47 | Surgery alone | 24 | 75 | 55 | 41 | 38 | 22 | NR |